Why the study?
Does serum CK-BB measured by ELISA correlate with clinical severity and mortality in head-injured patients?
Does serum CK-BB measured by ELISA correlate with clinical severity and mortality in head-injured patients?
Serum CK-BB measured by ELISA serves as a reliable prognostic biomarker in head-injured patients, with levels >100 micrograms/l predicting mortality.
The clinical value of serum brain specific creatine kinase (CK-BB) was assessed in head injured patients (group A) using a new enzyme-linked immunosorbent assay (ELISA). The results were compared to healthy controls (group B) and patients post-myocardial infarction (group C). None of the head injured patients had undergone a surgical procedure or ventricular puncture. CK-BB was significantly higher in group A than in controls. The level of CK-BB in group A was inversely proportional to the Glasgow Coma Scale on admission. All patients with a CK-BB greater than 100 micrograms/l died. The ELISA technique is a simple and reliable assay with prognostic significance in patients with head injury and has wider clinical application than the previously described radioimmunoassay methods.
No takes yet. Share an insight, caveat, or question.
Curley et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: